Telmisartan Teva
Withdrawn
telmisartan
Medicine
Human
Withdrawn
On 19 May 2021, the European Commission withdrew the marketing authorisation for Telmisartan Teva (telmisartan) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.
Telmisartan Teva was granted marketing authorisation in the EU on 26 January 2010 for the treatment of essential hypertension. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.
Telmisartan Teva is a generic medicine of Micardis. There are other generic medicinal products of Micardis authorised and marketed in the EU.
The European Public Assessment Report (EPAR) for Telmisartan Teva is updated to indicate that the marketing authorisation is no longer valid.
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
Treatment of essential hypertension in adults